Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PNLIP | P16233 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151867 | 0.88 | KCNK3 (0.40) | CYP3A4TSHRAKR1C2AKR1C1PNLIP | |
| SCHEMBL10986650 | 0.76 | HTT (0.52) | CYP3A4TSHRKMT2ALMNAHTT | |
| SCHEMBL10780641 | 0.75 | POLB (0.41) | CYP3A4TSHRKMT2AHTTMAPT | |
| SCHEMBL617661 | 0.70 | MAPT (0.47) | CYP3A4KMT2ALMNAHTTMAPT | |
| SCHEMBL10575131 | 0.68 | SMN1; SMN2 (0.41) | CYP3A4TSHRLMNAHTTMAPT | |
| SCHEMBL17071867 | 0.67 | POLB (0.43) | TSHRMAPTNPC1HPGDRAB9A | |
| SCHEMBL8894587 | 0.67 | CYP3A4 (0.50) | CYP3A4TSHRKMT2ALMNAHTT | |
| SCHEMBL6742081 | 0.67 | HTT (0.55) | CYP3A4TSHRKMT2ALMNAHTT | |
| SCHEMBL11274091 | 0.67 | LMNA (0.71) | CYP3A4TSHRKMT2APTGDR2LMNA | |
| SCHEMBL10455965 | 0.67 | NPC1 (0.48) | CYP3A4KMT2ALMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565430-B1 | BIGUANIDE DERIVATIVES | JACOBUS PHARMA CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7563792-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2008-07-24 | — | — | US | disclosed |
| US-7256218-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1565430-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL CO. INC. (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | QDPR, DHODH, GLMN | CYP3A4 2097/4885TSHR 1710/4885KMT2A 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.